ReviewClinical ophthalmology (Auckland, N.Z.)2022
Macular Telangiectasia Type 2: A Comprehensive Review.
Review in Clinical ophthalmology (Auckland, N.Z.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Anti-Vascular Endothelial Growth Factor Treatment Outcomes in Macular Telangiectasia: A Systematic Review.Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde · 2025Pooled it
- Macular Telangiectasia Type 2: A Case Series.Cureus · 2026Article
- Prevalence and Visual Acuity Characteristics of Patients with Macular Telangiectasia.Ophthalmology and therapy · 2026Article
- Association between AREDS/2 supplementation and structural and functional progression in macular telangiectasia type 2.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Article
- Eye Dominance and Testing Order Effects in the Circularly-Oriented Macular Pigment Optical Density Measurements.Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists) · 2026Article
- Expanding horizons of intravitreal anti-vascular endothelial growth factor therapy in retinal diseases.Indian journal of ophthalmology · 2026Review
- Is Macular Telangiectasia Type 2 Associated with Hearing Loss and Cochlear Dysfunction? A Prospective Case-Control Study.Diagnostics (Basel, Switzerland) · 2026Article
- Macular Telangiectasia Type 2: The Role of Optical Coherence Tomography and Management Options.Journal of clinical medicine · 2026Review
- Results from a Phase I Extension Study of Ciliary Neurotrophic Factor in Patients with Macular Telangiectasia Type 2.Ophthalmology science · 2026Article
- Article
- Macular Telangiectasia Type 2: Long-Term Disease Progression and Management of Complications.Turkish journal of ophthalmology · 2025Article
- Revakinagene Taroretcel: First Approval.Molecular diagnosis & therapy · 2025Review
- A case of macular telangiectasia type 2 with bilateral macular holes: Imaging features and surgical management.Medicine · 2025Article
- Plasmid Gene Therapy for Monogenic Disorders: Challenges and Perspectives.Pharmaceutics · 2025Review
- Macular pigment optical density and measurement technology based on artificial intelligence: a narrative review.International journal of ophthalmology · 2025Review
- Tamoxifen Retinopathy and Macular Telangiectasia Type 2: Case-Based Differential Diagnosis.Beyoglu eye journal · 2025Article
- High-Resolution Imaging in Macular Telangiectasia Type 2: Case Series and Literature Review.Diagnostics (Basel, Switzerland) · 2024Article
- Müller Glial Cells in the Macula: Their Activation and Cell-Cell Interactions in Age-Related Macular Degeneration.Investigative ophthalmology & visual science · 2024Review
- Intraretinal hyperreflective line: potential biomarker in various retinal disorders.Medical hypothesis, discovery & innovation ophthalmology journal · 2024Article
- Baseline demographic, clinical and multimodal imaging features of young patients with type 2 macular telangiectasia.International journal of retina and vitreous · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Macular telangiectasia Type 2 (MacTel) is a gradually progressive disease that affects the quality of life by impairing both distant and near vision. It had previously been considered a vascular condition, but recent evidence suggests a neurodegenerative etiology, with primary involvement of Muller cells. Retinal pigment epithelium (RPE) hyperplasia and subretinal neovascularization (SNV) are responsible for most of the vision loss in advanced cases. Neurotrophic factors in the non-proliferative phase and intravitreal anti-Vascular Endothelial growth factor (VEGF) in the proliferative phase have shown to retard the progression of the disease. This review will discuss the pathophysiology, clinical features, important diagnostic imaging studies and available treatment options for MacTel.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.